Here’s everything that you should know:

1. The Ministry of Health and Prevention (MoHAP) announced that they have received a green signal for the registration and use of the drug – Biogen’s Aduhelm after it was approved by the Food and Drug Administration
2. This drug is said to reduce, amyloid-beta plaques in the brain during the treatment
3. Amyloid-beta plaque is a hard, insoluble accumulation of beta-amyloid proteins that clump together between the nerve cells in the brain of Alzheimer’s disease patients.

This drug will provide early-stage Alzheimer patients and their families a ray of hope, especially the healthcare providers as they have been waiting for scientific progress in this regard for decades